I can IDENTIFY WHEN TO TREAT - The NCCN Clinical Practice Guidelines in Oncology
(NCCN Guidelines®) for Waldenström Macroglobulinaemia/ Lymphoplasmatic Lymphoma outline key clinical and laboratory
indications for treatment initiation (Table 2).¹

WHEN TO START TREATMENT

Treatment selection should be directed by the age and overall fitness of your patient, and clinical presentation.^1,2

• Studies show that aggressive therapies may be appropriate in younger patients with symptomatic MCL^1,2
• A “watch and wait” strategy for patients with asymptomatic, low MIPI or elderly MCL patients should be considered^1,2